Lucid Diagnostics

Lucid Diagnostics

Medical Equipment Manufacturing

New York, NY 7,005 followers

Lucid Diagnostics is an esophageal cancer prevention medical diagnostics company. Nasdaq: LUCD

About us

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device.

Industry
Medical Equipment Manufacturing
Company size
51-200 employees
Headquarters
New York, NY
Type
Public Company
Founded
2018

Locations

Employees at Lucid Diagnostics

Updates

Affiliated pages

Similar pages

Browse jobs

Funding

Lucid Diagnostics 4 total rounds

Last Round

Post IPO debt

US$ 21.9M

See more info on crunchbase